Australia markets closed

Twist Bioscience Corp (0ME.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
26.49+0.99 (+3.88%)
At close: 07:07PM CET
Full screen
Previous close25.50
Open25.30
Bid26.75 x 280000
Ask27.06 x 190000
Day's range25.30 - 26.49
52-week range20.44 - 57.82
Volume0
Avg. volume29
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date03 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Twist Bioscience Begins Shipping Commercial Product from Synthetic DNA Manufacturing Factory of the Future

    SOUTH SAN FRANCISCO, Calif., January 26, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the shipments of the first products from its second manufacturing site, the Factory of the Future, in Wilsonville, Oregon.

  • Business Wire

    Twist Bioscience to Report Fiscal 2023 First Quarter Financial Results on Friday, February 3, 2023

    SOUTH SAN FRANCISCO, Calif., January 19, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022, before the opening of the market on Friday, February 3, 2023. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. East

  • Business Wire

    Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

    SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. & ROSTOCK, Germany & BERLIN, January 10, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rar